Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.73 |
| ▸ | MIF | P14174 | 7/20 | 0.55 |
| ▸ | CD74 | P04233 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.48 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.48 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | LPO | P22079 | 1/20 | 0.47 |
| ▸ | CMA1 | P23946 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20237370 | 0.86 | MIF (0.74) | POLBMIFCD74KMT2AMEN1 | |
| SCHEMBL17156223 | 0.85 | KDM4E (0.56) | POLBMIFKMT2AMEN1MAPT | |
| SCHEMBL17156221 | 0.80 | MIF (0.68) | POLBMIFCD74MAPTTSHR | |
| SCHEMBL17156099 | 0.80 | IDO1 (0.71) | POLBMIFCD74KMT2AMEN1 | |
| SCHEMBL17165038 | 0.80 | MIF (0.57) | POLBMIFMAPTSMN1; SMN2SIGMAR1 | |
| SCHEMBL17156136 | 0.80 | MIF (0.72) | POLBMIFCD74KMT2AMEN1 | |
| SCHEMBL17156181 | 0.80 | ALDH1A1 (0.54) | POLBMIFCD74MAPTTSHR | |
| SCHEMBL17156208 | 0.79 | POLB (0.46) | POLBMIFKMT2AMEN1MAPT | |
| SCHEMBL17156087 | 0.79 | KDM4E (0.53) | POLBMIFKMT2ATSHRSMN1; SMN2 | |
| SCHEMBL17156133 | 0.78 | MIF (0.51) | POLBMIFKMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10160732-B2 | MIF inhibitors | MIFCARE (FR) | 2018-12-25 | — | — | US | claimed |
| EP-2929882-B1 | MIF inhibitors | MIFCARE (FR) | 2018-06-13 | — | — | EP | claimed |
| US-20170029387-A1 | MIF INHIBITORS | APAXEN (BE) | 2017-02-02 | — | — | US | claimed |
| WO-2015155358-A1 | MIF INHIBITORS | MIFCARE (FR) | 2015-10-15 | — | — | WO | claimed |
| US-10160732-B2 | MIF inhibitors | MIFCARE (FR) | 2018-12-25 | — | — | US | disclosed |
| EP-2929882-B1 | MIF inhibitors | MIFCARE (FR) | 2018-06-13 | — | — | EP | disclosed |
| US-20170029387-A1 | MIF INHIBITORS | APAXEN (BE) | 2017-02-02 | — | — | US | disclosed |
| US-20170029387-A1 | MIF INHIBITORS | APAXEN (BE) | 2017-02-02 | — | — | US | disclosed |
| US-20170029387-A1 | MIF INHIBITORS | APAXEN (BE) | 2017-02-02 | — | — | US | disclosed |
| EP-2929882-A1 | MIF inhibitors | Mifcare (FR) | 2015-10-14 | — | — | EP | disclosed |
| EP-2929882-A1 | MIF inhibitors | Mifcare (FR) | 2015-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10160732-B2 | MIF inhibitors | MIF, MSR1, MMP12 | POLB 3221/4885MIF 1/4885CD74 23/4885 |
| US-20170029387-A1 | MIF INHIBITORS | MIF, MSR1, MMP12 | POLB 3221/4885MIF 1/4885CD74 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.